A Multicenter, Open Label, 2 Period Cross-Over Study to Evaluate the PK of a 8 Week Continuous Treatment With 1x300mg/d and 2x300mg/d Tobramycin Inhaled With a 'Soft Mist' Nebulizer in Cystic Fibrosis (CF) Subjects.

Trial Profile

A Multicenter, Open Label, 2 Period Cross-Over Study to Evaluate the PK of a 8 Week Continuous Treatment With 1x300mg/d and 2x300mg/d Tobramycin Inhaled With a 'Soft Mist' Nebulizer in Cystic Fibrosis (CF) Subjects.

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Tobramycin (Primary)
  • Indications Pseudomonal infections
  • Focus Pharmacokinetics
  • Sponsors Novartis
  • Most Recent Events

    • 30 Nov 2015 Results published in the Journal of Antimicrobial Chemotherapy
    • 31 Aug 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 31 Aug 2010 Actual end date (Aug 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top